Privately-held Dance Biopharm said yesterday that it raised $24.5 million in a private equity round to help fund the development of its inhaled insulin product.
SternAegis Ventures was the exclusive placement agent for the offering. Molex Ventures, an electronics company working with Dance to develop a connected insulin delivery device, contributed to the round.
Get the full story at our sister site, Drug Delivery Business News.
The post Dance Biopharm raises $24m for inhaled insulin device appeared first on MassDevice.